Recommended Pages at hgsi.com
HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE FDA APPROVAL OF BENLYSTA® (BELIMUMAB) FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS - HGS
hgsi.com — “Human Genome Sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease.” View full resource at hgsi.com
Most Recently Shared on March 10, 2011 at 5:41 pm By:
Lupus Foundation Health Organization
@BigFire8 Not that I am personally aware of. You can learn more about the drug on HGSI's website http://bit.ly/i4RDJX
Benlysta approved:good news 4 patients w/ mild SLE, joint,skin problems despite prednisone plaquenil and MTX,AZA or MMF http://bit.ly/gTKKNF
hgsi.com — “Benlysta approved:good news 4 patients w/ mild SLE, joint,skin problems despite prednisone plaquenil and MTX,AZA or MMF http://bit.ly/gTKKNF” View full resource at hgsi.com
Most Recently Shared on March 10, 2011 at 1:06 am By:
Lupus Doctor Doctor, Internist, Rheumatologist, and Physician
Benlysta approved:good news 4 patients w/ mild SLE, joint,skin problems despite prednisone plaquenil and MTX,AZA or MMF http://bit.ly/gTKKNF
HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE FDA APPROVAL OF BENLYSTA® (BELIMUMAB) FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS - HGS
hgsi.com — “Human Genome Sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease.” View full resource at hgsi.com
Most Recently Shared on March 10, 2011 at 12:51 am By:
Lisa Jarvis Science Enthusiast
$HGSI and $GSK PR on approval of #lupus drug Benlysta (includes label info): http://bit.ly/fSvunc
HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE FDA EXTENSION OF BENLYSTA® PDUFA TARGET DATE TO MARCH 10, 2011 - HGS
hgsi.com — “Human Genome Sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease.” View full resource at hgsi.com
Most Recently Shared on December 3, 2010 at 9:23 pm By:
Scott Hensley Health Organization
RT @lisamjarvis: FDA extends PDUFA date for $HGSI and $GSK lupus drug Benlysta to March 10, 2011 (was Dec 10) http://bit.ly/hjKvfM
HUMAN GENOME SCIENCES RECEIVES COMPLETE RESPONSE LETTER FROM FDA ON ZALBIN" BLA FOR CHRONIC HEPATITIS C - HGS
hgsi.com — “Human Genome Sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease.” View full resource at hgsi.com
Most Recently Shared on October 5, 2010 at 11:04 am By:
Lisa Jarvis Science Enthusiast
as expected, $HGSI gets complete response letter for hep C drug Zalbin, development discontinued: http://bit.ly/df0nN9
HUMAN GENOME SCIENCES ANNOUNCES RESULTS OF RANDOMIZED PHASE 2 TRIAL OF MAPATUMUMAB IN NON-SMALL CELL LUNG CANCER - HGS
hgsi.com — “Human Genome Sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease.” View full resource at hgsi.com
Most Recently Shared on March 17, 2010 at 1:08 pm By:
John Carroll Health Communicator
HGS' lung cancer drug flunks Phase 2. http://bit.ly/bTu1Tu
HUMAN GENOME SCIENCES REPORTS INCREASING MOMENTUM TOWARD COMMERCIALIZATION AND ANNOUNCES 2010 GOALS AT JPMORGAN HEALTHCARE CONFERENCE - HGS
hgsi.com — “Human genome sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease.” View full resource at hgsi.com
Most Recently Shared on January 12, 2010 at 3:15 pm By:
Human Genome Sciences sets key goals for Benlysta in 2010: http://ow.ly/VDjS - Asking for FDA approval, unveiling more results from BLISS-76
HUMAN GENOME SCIENCES SUBMITS BIOLOGICS LICENSE APPLICATION TO FDA FOR ZALBIN" - HGS
hgsi.com — “Human Genome Sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease.” View full resource at hgsi.com
Most Recently Shared on November 25, 2009 at 2:31 pm By:
eyeonfda Pharma and Health Lawyer
FOR HEP C - HUMAN GENOME SCIENCES SUBMITS BIOLOGICS LICENSE APPLICATION TO FDA FOR ZALBINâ„¢ - http://ow.ly/FyFH
HUMAN GENOME SCIENCES RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR RAXIBACUMAB BIOLOGICS LICENSE APPLICATION - HGS
hgsi.com — “Human Genome Sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease.” View full resource at hgsi.com
Most Recently Shared on November 16, 2009 at 1:28 pm By:
eyeonfda Pharma and Health Lawyer
HUMAN GENOME SCIENCES RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR RAXIBACUMAB FOR ANTHRAX TRMT - http://ow.ly/CJhC
HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE POSITIVE RESULTS IN SECOND OF TWO PHASE 3 TRIALS OF BENLYSTA" IN SYSTEMIC LUPUS ERYTHEMATOSUS - HGS
hgsi.com — “Human Genome Sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease.” View full resource at hgsi.com
Most Recently Shared on November 2, 2009 at 5:17 am By:
Benlystaâ„¢ trial results in an historic research breakthrough and victory for people with lupus! http://bit.ly/y1iDD
HUMAN GENOME SCIENCES TO HOST NOVEMBER 2ND CONFERENCE CALL TO DISCUSS TOP-LINE RESULTS FROM SECOND PHASE 3 TRIAL OF BENLYSTA" (BELIMUMAB) IN SYSTEMIC LUPUS ERYTHEMATOSUS - HGS
hgsi.com — “Human Genome Sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease.” View full resource at hgsi.com
Most Recently Shared on October 29, 2009 at 3:39 pm By:
Stay tuned Monday for results from HGS's second Phase 3 clincal trial for Benlysta, a new treatment in development... http://bit.ly/4oivM9
HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE FULL PRESENTATION AT ACR OF POSITIVE PHASE 3 STUDY RESULTS FOR BENLYSTA" IN SYSTEMIC LUPUS ERYTHEMATOSUS - HGS
hgsi.com — “Human Genome Sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease.” View full resource at hgsi.com
Most Recently Shared on October 20, 2009 at 2:41 pm By:
HGS presents at ACR: BENLYSTA significantly reduced SLE disease activity, disease flare rates and fatigue;... http://bit.ly/vzIj
